Navigation Links
Results of the POSEIDON trial presented at TCT 2012
Date:10/25/2012

MIAMI, FL OCTOBER 25, 2012 A hydration regimen tailored to the patient's fluid status was effective in reducing damage to kidneys in patients undergoing cardiac catheterization, according to a study presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

Contrast-induced acute kidney injury (CI-AKI), or contrast-induced nephropathy, refers to kidney damage that may occur due to the use of contrast dye that is necessary for visualization during catheterization and other procedures. Hydration remains the cornerstone for the prevention of kidney damage. However, there are no well-defined practical hydration protocols available for the prevention of CI-AKI. The Prevention of Contrast Renal Injury with Different Hydration Strategies (POSEIDON) trial investigated a novel sliding scale hydration protocol based upon routine invasively obtained left ventricular end-diastolic pressure measurements (LVEDP) in patients undergoing cardiac catheterization.

Patients undergoing coronary angiography with stable renal insufficiency (an estimated GFR <60 mL/min/1.73m2) and one additional CI-AKI risk factor were randomized 1:1 to an LVEDP guided hydration strategy or a standard hydration strategy.

Both groups received 0.9 percent saline at 3 mL/kg for at least one hour prior to cardiac catheterization. The LVEDP was measured in all patients at the start of the procedure and prior to contrast administration. In the LVEDP group, the fluid rate was adjusted according to the patients' LVEDP as follows: 5 mL/kg/hr for LVEDP <13 mmHg; 3 mL/kg/hr for 13-18 mmHg; 1.5 mL/kg/hr for >18 mmHg.

The standard hydration group was hydrated at 1.5 mL/kg/hr. The fluid rate was set at the start of the procedure (prior to contrast exposure), continued during the procedure, and for four hours post-procedure. The primary outcome, CI-AKI, was defined as a greater than 25 percent or greater than 0.5 mg/dl increase in serum creatinine an indicator of kidney damage up to four days post-procedure.

There were 396 patients randomized, 196 in the LVEDP group and 200 in the standard hydration group. Kidney damage was found in 6.7 percent of the LVEDP guided hydration group and in 16.3 percent of the standard hydration group (P = 0.005). There were no significant differences between groups for baseline renal function or LVEDP. The relative risk (95 percent confidence interval) for LVEDP-guided hydration versus standard hydration was 0.41 (0.22-0.79). The absolute risk difference was -9.5 percent in favor of LVEDP guided hydration; therefore, 11 patients would need to be treated to prevent one CI-AKI event.

"This is the first trial to test the hypothesis of a left ventricular end diastolic pressure-guided hydration strategy for prevention of contrast nephropathy. We found that this technique resulted in a significant 59 percent relative and 10 percent absolute reduction in contrast nephropathy," said lead researcher Somjot Brar, MD, MPH. Dr. Brar is an Interventional Cardiologist & Vascular Specialist at Kaiser Permanente in Los Angeles, CA and an Assistant Clinical Professor of Medicine at the University of California, Los Angeles.

"This is an easily implemented protocol that can be readily adapted in both inpatient and outpatient settings," Dr. Brar said.


'/>"/>
Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. 1-year results of ADAPT-DES presented at TCT 2012
2. Comparison of Obesity Surgeries Turns Up Surprising Results
3. Results from study of Mead Johnsons Enfamil® Human Milk Fortifier Acidified Liquid published in Pediatrics
4. Missed Diagnoses in ICU Often Have Deadly Results: Review
5. Anti-clotting drugs yield similar results
6. Late-Night Cramming May Hurt School Test Results
7. New survey: Women want to SEE breast reconstruction results before cancer surgery
8. Weight-loss surgery results in positive changes in social life, medical conditions
9. Many Test Results Left Unread as Patients Leave Hospital: Study
10. 7-Day Stuttering Therapy May Get Results, Study Says
11. Swaziland HIV incidence results announced at AIDS 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... ... of Eden”: retells the stories of three Bible figures in modern terms. “Just What ... trader, horse farmer, artist and a former GM journeyman. Born in 1953 in Portland, ... to Dayton, Ohio, where Penny graduated high school. At sixteen, she toured France to ...
(Date:5/24/2017)... ... 2017 , ... Last month, representatives from Rendina Healthcare Real ... officials to celebrate the grand opening of the 87,000 square foot medical office/ICU ... its ongoing relationship with RWJBarnabas Health, New Jersey’s largest health system. Two years ...
(Date:5/24/2017)... ... May 24, 2017 , ... Altec Products, Inc., a ... 2017 – a one-day technology conference in San Diego, CA. , At nVerge ... users to fully utilize and enhance their Sage ERP solutions by providing improved visibility ...
(Date:5/24/2017)... ... , ... Dr. Manju R. Kejriwal, a leading Ohio dentist, is now welcoming ... referral. Dr. Kejriwal understands the emotional and financial toll traditional orthodontics can take on ... no longer need to feel the esthetic effects of wires and brackets when they ...
(Date:5/24/2017)... Hattiesburg, Mississippi (PRWEB) , ... May 24, 2017 , ... ... fact is his has the ability to sell luxury homes anywhere on the planet. ... in the county side from Hattiesburg to Houston city-scapes. A quick search of “11 ...
Breaking Medicine News(10 mins):
(Date:5/24/2017)... 24, 2017  ivWatch LLC today announced the ... Board to enable seamless integration of ivWatch,s groundbreaking ... infusion pumps and other devices. By integrating ivWatch ... to help health care customers deliver a higher ... to IV therapy. "The ivWatch OEM ...
(Date:5/18/2017)... 2017  Bayer announced today that the latest research ... at the 53 rd Annual Meeting of the ... 2-6 in Chicago . ... colorectal, liver and thyroid cancers, as well as lymphomas, ... CHRONOS-1 trial of copanlisib in patients with relapsed or ...
(Date:5/10/2017)... MARLBOROUGH, Mass., May 10, 2017 Hologic, Inc. ... financial results for the fiscal second quarter ended April ... (EPS) of $1.84 increased 666.7% compared to the prior ... business resulted in a significant gain, while non-GAAP diluted ... increased 3.2%, or 3.8% in constant currency terms.  Excluding ...
Breaking Medicine Technology: